Analyst upgrades kept flowing on Thursday, August 6, with JP Morgan making a bold Overweight call on Charles River and lifting its target to $310 from $180, Argus turning bullish on Roper Technologies, Wolfe Research raising Global Payments, Jefferies flipping J&J Snack Foods to Buy, and TD Cowen upgrading TPG. The July 29 FOMC held rates at 3.50%-3.75%, and CME Group's FedWatch tool still assigns roughly an 80% probability to no cuts through 2026. The five names below span life sciences, consumer staples, payments, industrial technology, and alternative asset management.
Charles River Laboratories (CRL) — JP Morgan turns bold on a biotech-funding comeback
Charles River is a global contract research organization providing preclinical drug discovery, safety assessment (DSA), research models, and manufacturing services to biotech and pharma. On August 6, JP Morgan analyst Casey Woodring upgraded from Neutral to Overweight with a $310 target (up from $180), citing a biotech-funding rebound flowing into DSA bookings. The upgrade followed the August 5 Q2 print: organic revenue up 0.1% (versus prior guidance for a low-single-digit decline), a 420 bp sequential operating-margin improvement to 20.5%, and raised full-year non-GAAP EPS guidance of $11.15-$11.45. Evercore ISI's Ross Muken raised his Outperform target to $300 from $260, and RBC Capital's Ryan Halsted raised his Outperform target to $282 from $215.
Shares traded at $258.79 on August 6, down 0.74%, with a market cap of $12.5 billion. The 52-week range is $144.26 to $267.74. The consensus rating is Strong Buy, with 9 of 12 covering analysts bullish, an average target of $240.83, a median of $232.50, a high of $310, and a low of $175.
Risks: The stock has already run more than 75% off its 52-week low, tightening the risk-reward; DSA-book conversion remains sensitive to biotech-funding cycles; and reported GAAP Q2 results included a net loss on impairment charges. Mizuho's Ann Hynes maintains Neutral with a $175 target.
J&J Snack Foods (JJSF) — Jefferies upgrades on Project Apollo margin engine
J&J Snack Foods is a specialty branded snack company (SUPERPRETZEL, Icee, Dogsters, Luigi's) selling into retail, foodservice, and frozen beverage channels. On August 6, Jefferies analyst Scott Marks upgraded from Hold to Buy with a $101 target (up from $81), citing Project Apollo's expanding margin contribution. The August 5 fiscal Q3 print: adjusted EPS of $1.96 versus $1.70-$1.80 consensus, revenue of $426 million (down 6.2% YoY), gross margin expanding 240 bp to 35.5%, and management raising annualized plant-consolidation savings to at least $20 million from $15 million.
Shares traded at $91.45 on August 6, up 8.02%, with a market cap of $1.7 billion and a trailing P/E of 35.34. The 52-week range is $68.87 to $116.32. The consensus is Strong Buy, with both covering analysts bullish, an average target of $110.50, a high of $120, and a low of $101.
Risks: Revenue is still declining year-over-year and Q3 missed the top line; retail volumes remain sensitive to slotting-fee investment and snack innovation; and coverage is thin, producing sharper reactions to individual moves. Benchmark's Todd Brooks cut his Buy target to $120 from $130 earlier this year.
Global Payments (GPN) — Wolfe Research flips to Outperform on post-close Worldpay setup
Global Payments provides payment technology and software services to merchants and financial institutions worldwide, and completed its Worldpay acquisition earlier this year. On August 6, Wolfe Research upgraded from Peer Perform to Outperform with a $110 target, citing the Q2 print and integration progress. The August 5 Q2 report: adjusted EPS of $3.46 (up 11.7% YoY, $0.02 ahead), adjusted net revenue of $3.16 billion (up ~4% normalized), and GAAP revenue of $3.32 billion (up 68.6% YoY on Worldpay). Argus's Stephen Biggar raised his Buy target to $110 from $95, and RBC's Daniel Perlin raised his Sector Perform target to $96 from $82.
Shares traded at $86.33 on August 6, down 1.32%, with a market cap of $21.4 billion. The 52-week range is $61.16 to $90.64. The consensus rating is Buy, with 6 of 16 covering analysts bullish, an average target of $92.25, a median of $92, a high of $111, and a low of $74.
Risks: Adjusted net revenue growth remains mid-single digits despite Worldpay; management flagged softer full-year revenue guidance and continued Middle East pressure; and integration on a large acquisition can weigh on near-term margins. Truist Securities' Matthew Coad maintains Hold with an $81 target.
Roper Technologies (ROP) — Argus upgrades on Q2 beat and 2026 guide raise
Roper operates a portfolio of application software, network software, and technology-enabled products businesses across healthcare, education, legal, insurance, and industrial markets. On August 6, Argus analyst Stephen Biggar upgraded from Hold to Buy with a $450 target, roughly 14% above spot, citing the Q2 beat and guidance raise. The July 23 Q2 report: revenue up 9% to $2.11 billion (organic +5%), GAAP DEPS up 233% to $11.62, adjusted DEPS up 10% to $5.38, and lifted full-year 2026 adjusted EPS guidance.
Shares traded at $393.20 on August 6, down 0.34%, with a market cap of $39.7 billion and a trailing P/E of 16.38. The 52-week range is $305.96 to $546.52. The consensus rating is Buy, with 8 of 14 analysts bullish, an average target of $479.71, a median of $460, a high of $625, and a low of $365.
Risks: The stock trades well below 2025 highs, indicating unresolved concerns around software-portfolio organic growth and capital-deployment returns; deal contribution can be uneven; and roughly one in five analysts is bearish. JP Morgan's Chigusa Katoku maintains Underweight with a $415 target.
TPG Inc. (TPG) — TD Cowen upgrades after Q2 fee-growth print
TPG is a global alternative asset manager investing across private equity, credit, real estate, growth, and impact strategies. On August 6, TD Cowen upgraded from Hold to Buy following the August 4 Q2 print: GAAP net income of $93 million, after-tax distributable earnings of $280 million ($0.69 per Class A share), and a declared dividend of $0.59 per share payable August 28, 2026. Revenue nearly doubled to $1.84 billion versus $921 million a year earlier. UBS's Michael Brown raised his Buy target to $65 from $59, and RBC's Bart Dziarski raised his Outperform target to $65 from $60.
Shares traded at $48.36 on August 6, up 0.93%, with a market cap of $18.5 billion, a trailing P/E of 55.58, and a trailing dividend yield near 5%. The 52-week range is $36.95 to $70.38. The consensus rating is Strong Buy, with 10 of 13 covering analysts bullish, an average target of $60.23, a median of $64, a high of $76, and a low of $45.
Risks: Fee-related earnings growth is tied to fundraising velocity, which can slow in a soft LP environment; performance-fee timing is lumpy; and the stock is still well below its 52-week high. Evercore ISI's Glenn Schorr maintains In-Line with a $47 target.
Found this helpful? Share it with others.